600,000 Bottles of Generic Adderall Recalled

Allergan’s Actavis recalls 54 lots of ADHD drug due to failed impurity tests, while awaiting Teva buyout approval.

Allergan Headquarters / Photo: locationoc.com
Allergan Headquarters / Photo: locationoc.com

According to a recent FiercePharma article, Actavis is voluntarily recalling 54 lots including four different dose forms of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets. The recall was initiated in February, but was just classified by the FDA as a Class II recall last week. Teva is awaiting regulatory approval for their $40.5 billion buyout of Allergan’s generic drug business, Actavis, but for now the responsibility of the recall falls on Allergan.

The deal inked between Teva and Allergan received approval from the European Union given that Teva sells off a majority of Allergan’s current generics business in the U.K. and Ireland. They also must jettison molecules in 24 other European countries.

Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
Medical Device Innovations Report